New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

DLC1 Polyclonal Antibody, Cy5 Conjugated

Applications

  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Predicted Reactivity

  • Human
  • Mouse
  • Rat
  • Cow
  • Pig
  • Horse
  • Rabbit
Overview
Catalog # bs-5801R-Cy5
Product Name DLC1 Polyclonal Antibody, Cy5 Conjugated
Applications IF(IHC-P), IF(IHC-F), IF(ICC)
Predicted Reactivity Human, Mouse, Rat, Cow, Pig, Horse, Rabbit
Specifications
Conjugation Cy5
Host Rabbit
Source KLH conjugated synthetic peptide derived from human DLC1
Immunogen Range 1-80/89
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 8655
Swiss Prot P63167
Subcellular location Cytoplasm
Synonyms LC8; PIN; DLC1; DLC8; LC8a; DNCL1; hdlc1; DNCLC1; Dynein light chain 1, cytoplasmic; 8 kDa dynein light chain; Dynein light chain LC8-type 1; Protein inhibitor of neuronal nitric oxide synthase; DYNLL1
Background Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 1 complex that are thought to be involved in linking dynein to cargos and to adapter proteins that regulate dynein function. Cytoplasmic dynein 1 acts as a motor for the intracellular retrograde motility of vesicles and organelles along microtubules. May play a role in changing or maintaining the spatial distribution of cytoskeletal structures. Binds and inhibits the catalytic activity of neuronal nitric oxide synthase. Promotes transactivation functions of ESR1 and plays a role in the nuclear localization of ESR1. Regulates apoptotic activities of BCL2L11 by sequestering it to microtubules. Upon apoptotic stimuli the BCL2L11-DYNLL1 complex dissociates from cytoplasmic dynein and translocates to mitochondria and sequesters BCL2 thus neutralizing its antiapoptotic activity.
Application Dilution
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200